News
Public · Published
United Therapeutics Corporation Stock 12‑Month Price Target Raised to $680.5, Implies 13% Upside
Estimates from 14 analysts raised United Therapeutics Corporation's average 12-month stock price target from $670.93 to $680.5. Based on the Nov. 3 closing price, the new target implies about 13% potential upside. The consensus rating remained Buy among 17 analysts: 14 Buys, two Holds and one Sell.
Published:
Updated:
What happened
Estimates from 14 analysts raised United Therapeutics Corporation’s average 12-month stock price target from $670.93 to $680.5. Based on the Nov. 3 closing price, the new target implies about 13% potential upside. The consensus rating remained Buy among 17 analysts: 14 Buys, two Holds and one Sell.
Confirmed
Global impact / market context
The higher average target signals a modest improvement in analysts’ expectations, but it is not a company forecast or a promise of returns. The broad range—from $368 to $850 per share—shows substantial disagreement, so the target offers limited certainty about future stock performance.
Analyst inference
The reported 13% upside is calculated from the Nov. 3 closing price, not a guaranteed return or a stated trading outcome. The estimates summarize analyst views; the supplied information gives no company results, business changes, or explanation for why the target rose.
Confirmed
What to watch
- Future analyst target changes could show whether the increase from $670.93 to $680.5 is sustained or reversed, while the wide forecast range highlights differing views. Analyst inference
- The article reports 14 Buys, two Holds and one Sell among 17 covering analysts; later rating changes would alter that stated consensus. Confirmed
- Compare subsequent company disclosures with analyst estimates to see whether new information supports changes to expected revenue, costs, or investment spending; none is described here. Analyst inference
Evidence
- Original source link unavailable